Friday, PPD Inc. (PPDI) said it has completed its acquisition of Excel PharmaStudies, Inc. The acquisition strengthens PPD's full range of drug development services in the country and positions it to capitalize on the tremendous growth of the outsourcing market in Asia Pacific. The acquisition significantly increases PPD's employee and client base in the region. Excel has more than 300 employees in China, and PPD now employs more than 750 professionals in Asia Pacific, the company said.
With this acquisition, PPD said it has expanded its capability to offer Phase II-IV clinical management, data management, biostatistics, regulatory and quality assurance services under a variety of operating models, ranging from functional to full service. This combination of Excel and PPD creates one of the largest CROs operating in China, a country that offers vast populations of potential patients, fast patient recruitment and large centralized hospitals. Excel will continue to operate under its brand with full access to PPD's global resources, clients and expertise.
For comments and feedback: editorial@rttnews.com